BC Innovations | Jan 23, 2018
Distillery Therapeutics

Cancer

INDICATION: Solid tumors Cell culture and mouse studies suggest combining Votrient pazopanib and a potassium channel inhibitor could help treat rhabdoid tumors. High throughput screening of a library of approved drugs in six human rhabdoid...
BioCentury | May 13, 2013
Product Development

An association for dissociation

Forest Laboratories Inc. 's investment and option deal with Trevena Inc. last week will support the translation of a successful mechanism for treating chronic heart failure into the acute setting, as well as the development...
BC Week In Review | Apr 25, 2011
Company News

Blue Ash Therapeutics, Forest Laboratories deal

Blue Ash granted Forest exclusive, worldwide rights to antiarrhythmic candidate azimilide . Last year, Blue Ash licensed the potassium channel blocker from Warner Chilcott plc (NASDAQ:WCRX, Dublin, Ireland), which acquired the product in 2009 from original...
BioCentury | Apr 25, 2011
Finance

Highlights of weekly biotech stock moves

Regulatory milestones Chelsea Therapeutics International Ltd. (NASDAQ:CHTP) gained $0.88 (22%) to $4.86 on Monday after clarifying the regulatory path in the U.S. for Northera droxidopa to treat neurogenic orthostatic hypotension (NOH). Chelsea still plans to...
BC Extra | Apr 20, 2011
Company News

Azimilide finds its way to Forest

Blue Ash Therapeutics LLC (Cincinnati, Ohio) granted Forest Laboratories Inc. (NYSE:FRX) exclusive, worldwide rights to antiarrhythmic candidate azimilide . Last year, Blue Ash licensed the potassium channel blocker from Warner Chilcott plc (NASDAQ:WCRX), which acquired the...
BC Week In Review | Nov 19, 2001
Clinical News

Azimilide: Phase III

In a placebo-controlled international Phase III study in 3,717 post-MI patients with a low left ventricular ejection fraction, azimilide had no adverse effect on all-cause mortality or survival. Patients at high risk of sudden death...
Items per page:
1 - 6 of 6